Early administration of AD medication and patient monitoring for disease progression via biomarker diagnosis are essential for treatment effectiveness. The development of AD pathology may be slowed by future treatments that target tau pathology and the use of combination therapy. Here, MAPT is linked to Alzheimer disease.